Cover Image
市場調查報告書

纖化症:開發中產品分析

Fibrosis - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 255947
出版日期 內容資訊 英文 97 Pages
訂單完成後即時交付
價格
Back to Top
纖化症:開發中產品分析 Fibrosis - Pipeline Review, H2 2015
出版日期: 2015年10月28日 內容資訊: 英文 97 Pages
簡介

本報告提供全球纖化症治療藥的開發趨勢調查,提供開發中產品各開發階段的比較分析,藥物標的,作用機制,給藥途徑,各類型分子的治療藥評估,再加上這個部門的最新趨勢,主要企業的檢討等。

簡介

  • 調查範圍

纖化症概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

纖化症:企業開發中的治療藥

纖化症:大學/機關研究中的治療藥

纖化症:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

纖化症:企業開發中的產品

纖化症:大學/機關研究中的產品

開發纖化症治療藥的企業

  • Genzyme Corporation
  • Capstone Therapeutics Corp.
  • Aastrom Biosciences, Inc.
  • Quark Pharmaceuticals, Inc.
  • 大正製藥
  • FibroGen, Inc.
  • InterMune, Inc.
  • Pfizer Inc.
  • SK Chemicals Co., Ltd.
  • UCB S.A.
  • Karo Bio AB
  • Lpath, Inc.
  • Pharmaxis Limited
  • ProMetic Life Sciences Inc.
  • HanAll Biopharma Co., Ltd.
  • Galectin Therapeutics, Inc.
  • Biotie Therapies Corp.
  • Galapagos NV
  • Digna Biotech, S.L.
  • AiCuris GmbH & Co. KG
  • Angion Biomedica Corp.
  • Siena Biotech S.p.A.
  • Intercept Pharmaceuticals, Inc.
  • KineMed, Inc.
  • Groove Biopharma
  • miRagen Therapeutics, Inc.
  • RuiYi Inc.
  • Fibrotech Therapeutics Pty. Ltd.
  • Neumedicines Inc.
  • Rhizen Pharmaceuticals SA
  • Inventiva SAS
  • Nogra Pharma Limited

纖化症:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各類型分子

藥物簡介

  • fresolimumab
  • PF-06473871
  • BTT-1023
  • SDP-051
  • Lpathomab
  • disitertide
  • ixmyelocel-T
  • AZX-100
  • noscapine
  • INT-767
  • GED-0507
  • MGN-4220
  • PBI-4050
  • PBI-4419
  • Tankyrase/Wnt Inhibitors
  • NMIL-121
  • GC-4403
  • RP6503
  • HL-156Fib
  • Project MITRA
  • FT-071
  • FT-061
  • FT-026
  • FT-011
  • SphK1 Program
  • SphK2 Program
  • NCE-401
  • AIC-649
  • PXS-4728-A
  • MicroRNA
  • Trophokine
  • ITMN-30162
  • KBP-7018
  • siRNA
  • ANG-4011
  • Lysine Fortifieds
  • FT-01
  • S1P3 Antagonist Progam
  • RYI-018
  • GC-4419等

纖化症:最近的開發平台趨勢

纖化症:暫停中的計劃

纖化症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7279IDB

Summary

Global Markets Direct's, 'Fibrosis - Pipeline Review, H2 2015', provides an overview of the Fibrosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fibrosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Fibrosis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Fibrosis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Fibrosis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Fibrosis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Fibrosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Fibrosis Overview
  • Therapeutics Development
    • Pipeline Products for Fibrosis - Overview
    • Pipeline Products for Fibrosis - Comparative Analysis
  • Fibrosis - Therapeutics under Development by Companies
  • Fibrosis - Therapeutics under Investigation by Universities/Institutes
  • Fibrosis - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Fibrosis - Products under Development by Companies
  • Fibrosis - Products under Investigation by Universities/Institutes
  • Fibrosis - Companies Involved in Therapeutics Development
    • Abeome Corporation
    • Acceleron Pharma, Inc.
    • Complexa, Inc.
    • Digna Biotech, S.L.
    • F. Hoffmann-La Roche Ltd.
    • FibroGen, Inc.
    • GlycoMimetics, Inc.
    • HanAll Biopharma Co., Ltd.
    • Isarna Therapeutics GmbH
    • Lycera Corp.
    • miRagen Therapeutics, Inc.
    • Neumedicines Inc.
    • Ribomic Inc.
    • RuiYi Inc.
    • Scholar Rock, Inc.
    • Siena Biotech S.p.A.
    • Silence Therapeutics Plc
    • SK Chemicals Co., Ltd.
    • UCB S.A.
    • XOMA Corporation
  • Fibrosis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ACE-2531 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antibodies for Fibrosis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antibody to Inhibit Transglutaminase 2 for Fibrosis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • disitertide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drug to Activate Insulin Like Growth Factor for Fibrosis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • G-XXX - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HL-156FIB - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IB-DMD - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ISTH-1047 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MGN-4220 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit IL-25 for Asthma, Fibrosis and Atopic Dermatitis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit TGF-beta 1 for Fibrosis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NCE-401 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NMIL-121 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NPH-09 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • P-006 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PRI-724 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RBM-003 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RBM-007 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RG-6069 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RNAi Oligonucleotide for Liver Diseases - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RYI-028 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit Galectin-3 for Fibrosis, Cancer and Cardiovascular Disease - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit LOXL2 for Fibrosis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit MicroRNA for Vascular Fibrosis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit Rho Kinase for Fibrosis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit Tankyrase/Wnt for Musculoskeletal, CNS and Oncology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Inflammatory Diseases and Fibrosis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Activate RXFP1 for Heart Failure and Fibrosis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Antagonize S1P3 for Inflammation, Neurodegenerative Diseases and Fibrosis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Procollagen C-Proteinase for Fibrosis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit SMURF2 for Fibrosis, Oncology and IBD - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit SphK1 for Oncology, Autoimmune Disorders, Fibrosis and Neurodegenerative Diseases - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Trophokine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • XOMA-089 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Fibrosis - Recent Pipeline Updates
  • Fibrosis - Dormant Projects
  • Fibrosis - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Fibrosis, H2 2015
  • Number of Products under Development for Fibrosis - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Comparative Analysis by Unknown Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Development by Companies, H2 2015 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2015
  • Fibrosis - Pipeline by Abeome Corporation, H2 2015
  • Fibrosis - Pipeline by Acceleron Pharma, Inc., H2 2015
  • Fibrosis - Pipeline by Complexa, Inc., H2 2015
  • Fibrosis - Pipeline by Digna Biotech, S.L., H2 2015
  • Fibrosis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
  • Fibrosis - Pipeline by FibroGen, Inc., H2 2015
  • Fibrosis - Pipeline by GlycoMimetics, Inc., H2 2015
  • Fibrosis - Pipeline by HanAll Biopharma Co., Ltd., H2 2015
  • Fibrosis - Pipeline by Isarna Therapeutics GmbH, H2 2015
  • Fibrosis - Pipeline by Lycera Corp., H2 2015
  • Fibrosis - Pipeline by miRagen Therapeutics, Inc., H2 2015
  • Fibrosis - Pipeline by Neumedicines Inc., H2 2015
  • Fibrosis - Pipeline by Ribomic Inc., H2 2015
  • Fibrosis - Pipeline by RuiYi Inc., H2 2015
  • Fibrosis - Pipeline by Scholar Rock, Inc., H2 2015
  • Fibrosis - Pipeline by Siena Biotech S.p.A., H2 2015
  • Fibrosis - Pipeline by Silence Therapeutics Plc, H2 2015
  • Fibrosis - Pipeline by SK Chemicals Co., Ltd., H2 2015
  • Fibrosis - Pipeline by UCB S.A., H2 2015
  • Fibrosis - Pipeline by XOMA Corporation, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Fibrosis Therapeutics - Recent Pipeline Updates, H2 2015
  • Fibrosis - Dormant Projects, H2 2015

List of Figures

  • Number of Products under Development for Fibrosis, H2 2015
  • Number of Products under Development for Fibrosis - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Routes of Administration, H2 2015
  • Number of Products by Stage and Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top